Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a few years ago that its use became mainstream. Originally crafted to help ...
GlobalData on MSN2d
Ascletis announces positive results in Phase Ib oral GLP-1RA trialThe Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Vapourtec’s R-Series flow chemistry system, equipped with a UV-150 photochemical reactor, has been cited in research by scientists* at Novo Nordisk in the C-terminal α-amination of peptides and ...
After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...
BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.
Feb. 3, 2025 /PRNewswire/ -- Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1 ...
BELLEVUE, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has ...
0.35-0.88), P=0.01), and AF after 1 year (RR, 0.58(95%CI: 0.36-0.94), P=0.01) was observed among GLP-1 RA group patients. Risk of Heart failure and VT was comparable. Conclusion: These findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback